MARC details
| 000 -CABECERA |
| campo de control de longitud fija |
05670nam a22003371i 4500 |
| 001 - NÚMERO DE CONTROL |
| campo de control |
398906 |
| 003 - IDENTIFICADOR DEL NÚMERO DE CONTROL |
| campo de control |
ES-MaUEC |
| 005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN |
| campo de control |
20240319173701.0 |
| 006 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA--CARACTERÍSTICAS DEL MATERIAL ADICIONAL |
| campo de control de longitud fija |
a|||| o|||| 00| 0 |
| 007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA--INFORMACIÓN GENERAL |
| campo de control de longitud fija |
cr nn 008mamaa |
| 008 - DATOS DE LONGITUD FIJA--INFORMACIÓN GENERAL |
| campo de control de longitud fija |
230628s2023 sz | o |||| 0|eng d |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
| Número Internacional Estándar del Libro |
9783031280122 |
| 024 7# - IDENTIFICADOR DE OTROS ESTÁNDARES |
| Número estándar o código |
10.1007/978-3-031-28012-2 |
| Fuente del número o código |
doi |
| 040 ## - FUENTE DE LA CATALOGACIÓN |
| Centro catalogador/agencia de origen |
ES-MaUEC |
| Lengua de catalogación |
spa |
| Centro/agencia transcriptor |
ES-MaUEC |
| Centro/agencia modificador |
ES-MaUEC |
| 050 #4 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO |
| Número de clasificación |
RA644 .C67 |
| Número de documento/Ítem |
2023 EB |
| 245 00 - MENCIÓN DE TÍTULO |
| Título |
Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19 |
| Mención de responsabilidad, etc. |
edited by Paul C. Guest |
| 250 ## - MENCIÓN DE EDICIÓN |
| Mención de edición |
1st ed. 2023 |
| 264 #1 - PRODUCCIÓN, PUBLICACIÓN, DISTRIBUCIÓN, FABRICACIÓN Y COPYRIGHT |
| Producción, publicación, distribución, fabricación y copyright |
Cham |
| Nombre del de productor, editor, distribuidor, fabricante |
Springer International Publishing |
| Fecha de producción, publicación, distribución, fabricación o copyright |
2023 |
| 300 ## - DESCRIPCIÓN FÍSICA |
| Extensión |
1 recurso en línea |
| 336 ## - TIPO DE CONTENIDO |
| Término de tipo de contenido |
texto |
| Código de tipo de contenido |
txt |
| Fuente |
rdacontent |
| 337 ## - TIPO DE MEDIO |
| Nombre/término del tipo de medio |
electrónico |
| Código del tipo de medio |
c |
| Fuente |
rdamedia |
| 338 ## - TIPO DE SOPORTE |
| Nombre/término del tipo de soporte |
recurso electrónico |
| Código del tipo de soporte |
cr |
| Fuente |
rdacarrier |
| 490 0# - MENCIÓN DE SERIE |
| Mención de serie |
Proteomics, Metabolomics, Interactomics and Systems Biology |
| Número Internacional Normalizado para Publicaciones Seriadas |
2730-6224 |
| Designación de volumen o secuencia |
1412 |
| 505 0# - NOTA DE CONTENIDO CON FORMATO |
| Nota de contenido con formato |
Chapter 1. The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology and Variants of Concern -- Chapter 2. Long-term Vaccination and Treatment Strategies for COVID-19 Disease and Future Coronavirus Pandemics -- Chapter 3. Consequences of the Lockdown - Domestic Violence during the COVID-19 Pandemic -- Chapter 4. Psychological distress impact of Coronavirus disease (COVID-19) outbreak on three continents: A systematic review and meta-analysis -- Chapter 5. A Molecular Biomarker-based Triage Approach for Targeted Treatment of Post-COVID-19 Syndrome Patients with Persistent Neurological or Neuropsychiatric Symptoms -- Chapter 6. Genetic Associations with Coronavirus Susceptibility and Disease Severity -- Chapter 7. COVID Diagnostics: from Molecules to Omics -- Chapter 8. Assessing Biomarkers in Viral Infection -- Chapter 9. Proteomic Investigation of COVID-19 Severity During the Tsunamis Second Wave in Mumbai -- Chapter 10. NMR-Metabolomics in COVID-19 Research -- Chapter 11. Potential Biomarkers of Mitochondrial Dysfunction Associated with COVID-19 Infection -- Chapter 12. Red Cell Distribution Width as a Prognostic Indicator for Mortality and ICU Admission in Patients with COVID-19 -- Chapter 13. Predicting the COVID-19 Patients Status using Chest CT Scan Findings: A Risk Assessment Model Based on Decision Tree Analysis -- Chapter 14. Inferring Recombination Events in SARS-CoV-2 Variants In Silico -- Chapter 15. Amplicon-based Nanopore Sequencing of Patients Infected by the SARS-CoV-2 Omicron (B.1.1.529) Variant in India -- Chapter 16. Perspectives on Rapid Antigen Tests for Downstream Validation and Development of Theranostics -- Chapter 17. Machine Learning and COVID-19: Lessons from SARS-CoV-2 -- Chapter 18. The Relationship between Psoriasis, COVID-19 Infection and Vaccination during Treatment of Patients -- Chapter 19. Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV; Sinopharm) and Short-term Clinical Outcomes in Vaccinated Solid Organ Transplant Recipients: A Prospective Cohort Study -- Chapter 20. Spices and Biomarkers of COVID-19: A Mechanistic and Therapeutic Perspective -- Chapter 21. Antiviral Mechanisms of Curcumin and its Derivatives in Prevention and Treatment of COVID-19: A review -- Chapter 22. Evaluation of Curcumin-Piperine Supplementation in COVID-19 Patients Admitted to the Intensive Care: A Double-Blind, Randomized Controlled Trial -- Chapter 23. Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases of COVID-19: A Hypothetical Approach -- Chapter 24. The Potential Effect of Royal Jelly on Biomarkers Related to COVID-19 Infection and Severe Progression -- Chapter 25. Statins: Beneficial Effects in Treatment of COVID-19 -- Chapter 26. Multiplex Immunoassay Approaches Using Luminex® xMAP® Technology for the Study of COVID-19 Disease -- Chapter 27. Rapid Detection of SARS-CoV-2 Variants of Concern by Genomic Surveillance Techniques. |
| 520 ## - SUMARIO, ETC. |
| Sumario, etc. |
The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected nearly every country and territory in the world. Although worldwide vaccination efforts have reduced the risk of serious disease outcomes, disparities in distribution have led to multiple waves of SARS-CoV-2 outbreaks and the emergence of variants of concern, some of which have enhanced infectivity and ability to evade existing vaccines. Hence there is an increasing interest in understanding the evolution of viruses like SARS-CoV-2, as well as improving our capacity to effectively current and manage future pandemics. This new volume reviews the most effective omic techniques for increasing our understanding of COVID-19, to improve diagnostics, prognostics, and genomic surveillance, and to facilitate development of effective treatments and vaccines. Chapters are written by an international team of experts and explore methods in the areas of genomics, transcriptomics, proteomics, and metabolomics. Techniques used to assess physiological function at the molecular level and artificial intelligence approaches used for more effective validation and translation of biomarker candidates into clinical use are also discussed. This book is an excellent resource for researchers studying biomarkers, virology, metabolic diseases, and infectious diseases, as well as clinical scientists, physicians, drug company scientists, and healthcare workers. |
| 988 ## - NOTA LOCAL 598 |
| Nota local 598 (boletines) |
Springer_BiomedLife_2023 |
| 650 #7 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
| Fuente del encabezamiento o término |
embne |
| 9 (RLIN) |
683668 |
| Término de materia o nombre geográfico como elemento de entrada |
COVID-19 |
| 856 40 - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS |
| Identificador Uniforme del Recurso |
https://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-28012-2 |
| Nota pública |
Acceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 ## - ELEMENTOS DE PUNTO DE ACCESO ADICIONAL (KOHA) |
| Fuente del sistema de clasificación o colocación |
Library of Congress Classification |
| Tipo de ítem Koha |
LIBRO-E NO PRÉSTAMO |
| 998 ## - DATOS ESTADÍSTICOS |
| Fecha de catalogación |
03/2024 |
| Tipo de materia |
E-book |
| Catalogador |
Isabel Alonso |
| Catalogado |
Sí |